Ditchcarbon
  • Contact
  1. Organizations
  2. Ardelyx, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Ardelyx, Inc. Sustainability Profile

Company website

Ardelyx, Inc., a biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for patients with gastrointestinal and renal diseases. Founded in 2007, Ardelyx has made significant strides in the industry, particularly with its focus on unique mechanisms of action that address unmet medical needs. The company’s flagship product, tenapanor, is designed to treat conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphataemia in patients with chronic kidney disease. Ardelyx's commitment to scientific excellence and patient-centric solutions has positioned it as a notable player in the biopharmaceutical landscape. With a robust pipeline and a focus on advancing healthcare, Ardelyx continues to make impactful contributions to the industry.

DitchCarbon Score

How does Ardelyx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Ardelyx, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

38%

Let us know if this data was useful to you

Ardelyx, Inc.'s reported carbon emissions

Ardelyx, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year. As such, there are no specific figures regarding their total emissions or breakdowns by Scope 1, 2, or 3. Additionally, the company has not outlined any formal reduction targets or commitments to the Science Based Targets initiative (SBTi). Despite the absence of emissions data and reduction initiatives, Ardelyx, Inc. is actively engaged in climate-related efforts as part of its corporate responsibility. The company is committed to understanding and managing its environmental impact, although specific details on their climate strategies or future commitments have not been disclosed. As the industry increasingly prioritises sustainability, Ardelyx, Inc. may consider establishing measurable targets and reporting frameworks to align with best practices in climate action.

How Carbon Intensive is Ardelyx, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Ardelyx, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Ardelyx, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Ardelyx, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Ardelyx, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Ardelyx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Ardelyx, Inc.'s Emissions with Industry Peers

Shire plc

IE
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated 27 days ago

Sarepta Therapeutics

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Boehringer Ingelheim Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 26 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251204.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy